Immunohistochemistry for the detection of renal cell carcinoma in effusion cytology

Diagnostic Cytopathology

Volumn 39, Issue 2, 2011, Pages 118-123

  Chute, Deborah J ^a   Kong, Christina S ^b   Stelow, Edward B ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

cytology; immunohistochemistry; PAX 2; renal cell carcinoma; serous effusion

Indexed keywords

CALRETININ; PROTEIN; PROTEIN B72 3; PROTEIN MOC31; TRANSCRIPTION FACTOR PAX2; TUMOR MARKER; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADENOCARCINOMA; ANTIBODY DETECTION; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOLOGY; CYTOPLASM; DISEASE MARKER; EFFUSION CYTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MESOTHELIUM CELL; PERITONEAL FLUID; PLEURA FLUID; PRIORITY JOURNAL;

CARCINOMA, RENAL CELL; CYTOLOGICAL TECHNIQUES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; KIDNEY; KIDNEY NEOPLASMS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 79251492367     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.21375     Document Type: Article

References (37)

1. Kumar AAV, Fausto N, Aster J, editors. Robbins and cotran pathologic basis of disease. 8th ed. Philadelphia: Saunders; 2009.
2. Janzen NK, Kim HL, Figlin RA, Belldegrun AS,. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-852.
3. Mai KT, Alhalouly T, Lamba M, Yazdi HM, Stinson WA,. Distribution of subtypes of metastatic renal-cell carcinoma: Correlating findings of fine-needle aspiration biopsy and surgical pathology. Diagn Cytopathol 2003; 28: 66-70.
4. Renshaw AA, Comiter CV, Nappi D, Granter SR,. Effusion cytology of renal cell carcinoma. Cancer 1998; 84: 148-152.
5. DeMay RM,. Fluids. The art and science of cytopathology. Vol. 1. Chicago: ASCP Press; 1996. p 257-316.
6. Carella R, Deleonardi G, D'Errico A, Salerno A, Egarter-Vigl E, Seebacher C, Donazzan G, Grigioni WF,. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: A study with logistic regression analysis. Am J Surg Pathol 2001; 25: 43-50.
7. Ordonez NG,. Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update. Am J Clin Pathol 1999; 112: 75-89.
8. Ordonez NG,. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989; 13: 276-291.
9. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F,. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126: 1757-1763.
10. Flens MJ, van der Valk P, Tadema TM, Huysmans AC, Risse EK, van Tol GA, Meijer CJ,. The contribution of immunocytochemistry in diagnostic cytology. Comparison and evaluation with immunohistology. Cancer 1990; 65: 2704-2711.
11. Liu JQL, Bostwick DG,. Immunohistology of the prostate, bladder, testis, and kidney. In:, Dabbs DJ, editor. Diagnostic immunohistochemistry. 2nd ed. Philadelphia: Elsevier; 2006. p 595-606.
12. Ordonez NG,. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: A comparative study. Hum Pathol 2004; 35: 697-710.
13. Ordonez NG,. Value of thyroid transcription factor-1. E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000; 24: 598-606.
14. Murugan P, Siddaraju N, Habeebullah S, Basu D,. Immunohistochemical distinction between mesothelial and adenocarcinoma cells in serous effusions: A combination panel-based approach with a brief review of the literature. [Review]. Ind J Pathol Microbiol 2009; 52: 175-181.
15. Jensen ML, Johansen P,. Immunocytochemical staining of serous effusions: An additional method in the routine cytology practice? Cytopathology 1994; 5: 93-103.
16. Shield PW, Callan JJ, Devine PL,. Markers for metastatic adenocarcinoma in serous effusion specimens. Diagn Cytopathol 1994; 11: 237-245.
17. Gupta RK, Kenwright DN, Fauck R, Lallu S, Naran S,. The usefulness of a panel of immunostains in the diagnosis and differentiation of metastatic malignancies in pericardial effusions. Cytopathology 2000; 11: 312-321.
18. Metzgeroth G, Kuhn C, Schultheis B, Hehlmann R, Hastka J,. Diagnostic accuracy of cytology and immunocytology in carcinomatous effusions. Cytopathology 2008; 19: 205-211.
19. Fetsch PA, Abati A,. Immunocytochemistry in effusion cytology: A contemporary review. [Review]. Cancer 2001; 93: 293-308.
20. Jensen ML, Johansen P,. Immunocytochemical staining of smears and corresponding cell blocks from serous effusions: A follow-up and comparative investigation. Diagn Cytopathol 1996; 15: 33-36.
21. Morgan RL, De Young BR, McGaughy VR, Niemann TH,. MOC-31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells. Cancer 1999; 87: 390-394.
22. Pu RT, Pang Y, Michael CW,. Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. Diagn Cytopathol 2008; 36: 20-25.
23. Oates J, Edwards C,. HBME-1, MOC-31, WT1 and calretinin: An assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000; 36: 341-347.
24. Pan CC, Chen PC, Ho DM,. The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: An immunohistochemical analysis of 328 cases. Histopathology 2004; 45: 452-459.
25. Wieczorek TJ, Krane JF,. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations. Cancer 2000; 90: 312-319.
26. Chhieng DC, Yee H, Schaefer D, Cangiarella JF, Jagirdar J, Chiriboga LA, Cohen JM,. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000; 90: 194-200.
27. Ordonez NG,. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998; 11: 929-933.
28. Nagel H, Hemmerlein B, Ruschenburg I, Huppe K, Droese M,. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract 1998; 194: 759-764.
29. Osborn M, Pelling N, Walker MM, Fisher C, Nicholson AG,. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas. Histopathology 2002; 41: 301-307.
30. Butnor KJ, Nicholson AG, Allred DC, Zander DS, Henderson DW, Barrios R, Haque AK, Allen TC, Killen DE, Cagle PT,. Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinoma. Arch Pathol Lab Med 2006; 130: 823-827.
31. Avery AK, Beckstead J, Renshaw AA, Corless CL,. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol 2000; 24: 203-210.
32. McGregor DK, Khurana KK, Cao C, Tsao CC, Ayala G, Krishnan B, Ro JY, Lechago J, Truong LD,. Diagnosing primary and metastatic renal cell carcinoma: The use of the monoclonal antibody 'Renal Cell Carcinoma Marker'. Am J Surg Pathol 2001; 25: 1485-1492.
33. Gokden N, Gokden M, Phan DC, McKenney JK,. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: An immunohistochemical study with comparison to renal cell carcinoma marker. Am J Surg Pathol 2008; 32: 1462-1467.
34. Gokden N, Mukunyadzi P, James JD, Gokden M,. Diagnostic utility of renal cell carcinoma marker in cytopathology. Appl Immunohistochem Mol Morphol 2003; 11: 116-119.
35. Mazal PR, Stichenwirth M, Koller A, Blach S, Haitel A, Susani M,. Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: A tissue microarray study. Mod Pathol 2005; 18: 535-540.
36. Daniel L, Lechevallier E, Giorgi R, Sichez H, Zattara-Cannoni H, Figarella-Branger D, Coulange C,. Pax-2 expression in adult renal tumors. Hum Pathol 2001; 32: 282-287.
37. Gokden N, Kemp SA, Gokden M,. The utility of Pax-2 as an immunohistochemical marker for renal cell carcinoma in cytopathology. Diagn Cytopathol 2008; 36: 473-477.